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Abstract
Healthcare as an industry is recognised as one of the most innovative. Despite heavy regulation, there is substantial scope for 
new technologies and care models to not only boost patient outcomes but to do so at reduced cost to healthcare systems and 
consumers. Promoting innovation within national health systems such as the National Health Service (NHS) in the United 
Kingdom (UK) has been set as a key target for health care professionals and policy makers. However, while the UK has a 
world-class biomedical research industry, several reports in the last twenty years have highlighted the difficulties faced by 
the NHS in encouraging and adopting innovations, with the journey from idea to implementation of health technology often 
taking years and being very expensive, with a high failure rate. This has led to the establishment of several innovation path-
ways within and around the NHS, to encourage the invention, development and implementation of cost-effective technologies 
that improve health care delivery. These pathways span local, regional and national health infrastructure. They operate at 
different stages of the innovation pipeline, with their scope and work defined by location, technology area or industry sector, 
based on the specific problem identified when they were set up. In this introductory review, we outline each of the major 
innovation pathways operating at local, regional and national levels across the NHS, including their history, governance, 
operating procedures and areas of expertise. The extent to which innovation pathways address current challenges faced by 
innovators is discussed, as well as areas for improvement and future study.
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Introduction
The industry of healthcare is recognised as one of the most 
innovative, with a record of driving multidisciplinary inno-
vation and fostering the adoption of new technologies. 
Health innovations tend to drive improvements in patient 
care as well as making this care increasingly cost-effective. 
This is of particular interest to healthcare systems such as 
the National Health Service (NHS) in the United Kingdom 
(UK), which seek to deliver high-quality care under tight 
budget constraints. The UK government’s spending on 
healthcare is approximately 10% of gross domestic prod-
uct (GDP) and an ageing population coupled with increases 
in long-term health conditions may only increase this in 
the foreseeable future [1]. The moral imperative towards 
improvements in patient care, and the need for these 
improvements to be cost-effective, means that facilitating 
innovation within and around health systems such as the 
NHS is a key priority for policy makers and clinical lead-
ers. Innovation in healthcare systems such as the NHS, is 
partly driven by intrapreneurship whereby members of the 
organisation pursue innovative ideas, but is also largely pro-
pelled by entrepreneurs creating ideas and partnering with 
healthcare partners. The NHS Long Term Plan, published in 
2019, highlighted the importance of innovation in the NHS, 
including the role it has in improving health outcomes, and 
committed the NHS to developing the infrastructure required 
for innovations to thrive [2]. It emphasised genomics as an 
innovation with potential to benefit both children and adults 
with rare diseases and/or cancer. Mental health was also 
highlighted as an area for future innovation efforts particu-
larly in regards to patient reported outcomes.
It has been noted that only a tiny proportion of medicines 
and medical devices which reach the market succeed and 
that the journey to market can sometimes cost in the billions 
of pounds and take over a decade [3]. In recent years, there 
have been numerous innovation pathways made accessible 
to early-stage innovators seeking to incorporate new tech-
nologies, services or digital innovations in the NHS. The 
introduction of these pathways has formed part of the dual 
strategy of improving health and creating wealth within an 
expanded British Life Sciences industry, led by the Depart-
ment of Health and Social Care and the Department for 
Business, Energy and Industrial Strategy [4–6].
Two key stages in an innovation process are invention 
and implementation, with an intervening development stage 
[7]. The invention stage is largely the responsibility of the 
’inventor(s)’; it consists of formulating the idea for an inno-
vation and developing the service or product. By the time the 
innovator approaches an innovation pathway, the invention 
stage would normally be resolved. However, it does present 
a substantial barrier to entry in many cases due to resources 
needed to develop a viable product. The implementation 
stage, on the other hand, can be even more resource inten-
sive, expensive and arduous. Since this stage consists of test-
ing the innovation and incorporating it in health systems, 
access to patients is typically required. Diffusion of innova-
tion is well characterised by the ‘Diffusion of Innovations’ 
theory proposed by Everett Rogers [8]. The theory dictates 
that the rate of adoption of an innovation is initially slow 
until it reaches a critical mass, after which spread of the 
innovation is self-sustaining. Therefore, the early period of 
the implementation stage can be particularly challenging for 
innovators to navigate, both because of the resources that are 
required and the need to identify potential early adopters.
It is in this implementation stage that innovation path-
ways may offer the greatest assistance to innovators. Funda-
mentally, these innovation pathways (or programmes) would 
help early-stage innovators find markets for their products. 
Additionally, they may help them with clinical testing and 
provide some funding. In some cases, they are compara-
ble to the services that accelerators or venture capital firms 
might provide to early-stage start-ups but they also provide 
specialist support to overcome healthcare-specific barriers 
to entry, such as the need for testing to ensure patient safety. 
In addition, many innovation pathways focus on forming a 
network between different stakeholders, simplifying aspects 
of the innovation pipeline.
These pathways support a wide range of innovations, 
ranging from medical devices to the development of new 
therapies. In many cases, the pathways are not specific to a 
certain type of innovation though there are some which have 
funding streams dedicated to certain avenues. The advent 
of industry 4.0 and machine learning, as well as the syner-
gies between different innovations, require that pathways be 
increasingly open given that the line between hardware and 
software innovations is increasingly blurred.
This introductory review seeks to offer an overview of 
innovation pathways available within and around the NHS 
with a view to provide insight to innovators and map out 
potential routes to market entry. In doing so, the review also 
seeks to illustrate any overlap or deficiencies in the current 
system.
Local Pathways
For innovations which are designed to impact patient care, a 
key component of their development is the need to test prod-
ucts and services in clinical environments. Local innovation 
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pathways integrated in hospital trusts permit this and offer 
resources to innovators seeking to implement their devices 
or services in the NHS. In local systems, there are numer-
ous stakeholders, including clinicians, patients, hospital 
trusts and Clinical Commissioning Groups (CCGs). CCGs 
plan health services in their local area and they are respon-
sible for two-thirds of the total NHS budget [9]. They work 
closely with hospitals and other healthcare providers in their 
local area to organise care pathways and may also collabo-
rate with Academic Health Science Networks (AHSNs; see 
below). The 2021 NHS White Paper set out further integra-
tion of local health and care, in the form of Integrated Care 
Systems (ICSs), which will succeed CCGs [10]. It is yet 
unclear how these changes will affect the innovation role of 
local health systems.
Individual trusts may offer their own services to innova-
tors, such as through the Test Beds programme. The Test 
Beds programme is a cross-government venture funded 
centrally to provide hospitals with the resources to support 
innovations at a local level [11]. Evidence is generated and 
evaluated to explore potential for wider implementation 
within the NHS.
NHS Vanguard
NHS Vanguard test sites are a similar venture to test beds, 
50 of which were selected in 2015 to propel development of 
innovative care models which could then be applied nation-
ally [12]. Vanguard sites consist of a group of stakeholders 
in a local area working together to test, measure and evaluate 
innovative care models. Though Vanguard sites are local 
pilots they receive national support and are intended to lead 
innovation at a national level. Vanguard sites operate in a 
range of fields, including general practice, acute care and 
care homes [13].
Academic Health Sciences Centres
Academic Health Sciences Centres (AHSCs) are accredited 
institutions in the UK which are recognised for their research 
and clinical expertise. They typically consist of a partner-
ship between a teaching hospital and a university. AHSCs 
have been established in North America for decades, but 
have expanded internationally and have been recognised in 
the United Kingdom since 2007 with the launch of Imperial 
College London’s AHSC [14]. AHSCs permit collaboration 
locally among research institutions and care providers as 
well as globally between international AHSCs. It has been 
noted that AHSC partnerships between universities and hos-
pitals may work to streamline approvals for clinical research 
by combining research infrastructure, for example “Joint 
Research Offices” [14].
Regional Pathways
As the 2018 RAND Europe review of UK Healthcare iden-
tified [15], there is a pressing need in the NHS innovation 
landscape for national policy which supports regional inno-
vation, and for regional success to then shape national policy 
and implementation. A similar point was emphasised in the 
2021 Health and Care White Paper [10]. Therefore, it is 
important to consider not only the local and national infra-
structure for innovation, but also regional networks.
Academic Health Science Networks
Perhaps the most important regional infrastructure for inno-
vation is the network of AHSNs [16, 17]. This network was 
established in 2013 following a series of policy and aca-
demic reports [18], recommending significant reform in 
the innovation landscape of England [4, 19] with the aim 
of improving regional health and creating wealth. AHSNs 
comprise 15 regional bodies (see Fig. 1), overseen by NHS 
England, which aim to coordinate regional NHS trusts, local 
government, charities and industry, helping to identify and 
spread health innovations [5, 16]. According to a 2016 
report compiled by the Office for Life Sciences and Monitor 
Deloitte [20], AHSNs represent the only body, regional or 
national, that has competency across every stage of innova-
tion, from idea to implementation. Their 2018/2019 report 
[17] contains more detail on the impact of AHSNs, including 
work on 3,630 innovations, creating 691 jobs and leveraging 
over £150million of investment.
The regional nature of AHSNs is important because they 
are well placed to take advantage of individual academic and 
industrial strengths of regions, using a range of strategies 
such as innovation scouts [21] and close partnership with 
university research hubs such as AHSCs [22] to identify and 
Fig. 1.  Area map of AHSNs.
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implement innovations. Examples include Digital Health 
London [23] delivered by MedCity, London’s AHSNs and 
AHSCs to develop the capital’s digital health infrastructure. 
Conversely, the universal coverage across England means 
that AHSNs can operate as a network to deliver national 
policy objectives. This includes both central programmes set 
at the beginning of each financial year [24] and unexpected 
challenges, for example implementing digital primary care 
in the COVID-19 crisis [25]. The first years of the AHSN 
network have widely been regarded as a success, and in 2017 
NHS England relicensed the networks, with an increase in 
funding [26]. There are still challenges to their operation, 
however. The only current full review of their performance, 
which covered their operation up to 2016, identified signifi-
cant variation in the practice of AHSNs [18]; some work 
on a looser basis, working with a wider range of companies 
and institutions, while others work more tightly with fewer 
institutions. This was partly due to pre-existing NHS struc-
tures, such as AHSCs and Collaborations for Leadership in 
Applied Health Research and Care (CLARHCs, now called 
ARCs, see below).
Applied Research Collaborations
Applied Research Collaborations (ARCs) are regional 
programmes funded by the National Institute of Health 
Research (NIHR). They replaced the CLAHRCs in 2019 
[27]. They are local partnerships between AHSNs, NHS, 
universities and charities; their 15 regions overlap almost 
directly with the regions of the AHSNs. From 2019, £135 
million will be invested, with the specific aim of increasing 
the rate at which innovative research is adopted in clinical 
practice. Each ARC takes a lead on a specific area based on 
the expertise of their region, with priority areas identified 
from RAND Europe’s ‘Future of Health (2017)’ [28] review. 
The Wessex ARC, for example, has a particular focus on 
ageing and dementia. Therefore, while the ARC remit is 
outside the traditional NHS innovation framework, they 
are a key piece within the regional innovation landscape; 
UCLPartners (North London AHSN) and the North Thames 
ARC, for example, have collaborated on a project investigat-
ing the long-term physical impacts of COVID-19 [29].
Regional Medicines Optimisation Committees
Regional Medicines Optimisation Committees (RMOCs) 
were established in 2016 to optimise the use of medicines 
across the NHS. Overseen by NHS England, they bring 
together decision makers, clinicians and patients. Accord-
ing to their 2019 operating model [30], their role is to share 
clinical best practice, speed implementation of new medi-
cines, instigate changes in use when evidence base changes, 
and reduce unwarranted variation in prescribing. There are 
currently four RMOCs covering England (South, London, 
Midlands and East, North), but there are plans to expand this 
number to seven from Autumn 2020. Similar to the ARCs, 
each RMOC takes a lead on a specific priority area (with 
these areas decided by NHS England Medicines Value Pro-
gramme). For example, the London RMOC leads work on 
polypharmacy [31]. Each RMOC is also able to propose 
its own priorities, suggested by local clinical care groups 
and area prescribing committees, which are then presented 
to the national priorities panel for consideration. Similar to 
the AHSN network, this facilitates top-down and bottom-up 
consideration of innovation priorities and policy changes.
National Pathways
Accelerated Access Collaborative
The Accelerated Access Collaborative (AAC), established in 
May 2019, is the umbrella body across the UK health inno-
vation ecosystem [32]. It was founded following the Accel-
erated Access Review led by Lord Darzi, which highlighted 
major areas of improvement for NHS Innovation [33]. The 
unit operates within NHS England and NHS Improvement, 
with board members representing each of its key partners 
[34]. With immediate goals of creating a “single front door 
to the innovation ecosystem”, including an online portal 
with information, and support and signposting for inno-
vations, the AAC strives to guide teams across the entire 
innovation pipeline, ranging from local testing provided by 
AHSNs, or evidence queries related to National Institute 
for Health and Care Excellence (NICE) submissions [35].
Since June 2019, the AAC have focussed on providing 
support for three categories of early-stage products (those 
yet to be approved by NICE) [36]:
• Advanced Therapy Medicinal Products
• Histology Independent Treatments for Cancer
• Artificial Intelligence
The AAC runs and coordinates a number of programmes 
across the UK innovation ecosystem. Some of these involve 
existing initiatives (such as AHSNs), some are dedicated 
AAC programmes such as the Clinical Entrepreneur Training 
Programme, where AAC provides training to help clinicians 
bring innovations to market [37], and some programmes run 
with other services, such as the NIHR Artificial Intelligence 
(AI) Scheme [38].
NHS Digital
Previously known as the Health and Social Care Informa-
tion Centre [39], NHS Digital is a public-facing body [40], 
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providing most web-services, statistical publications, and 
data management systems used within the NHS [41]. Their 
focus is largely centred on the current infrastructure of the 
NHS, and thus they tend to have a restricted role in early 
product development; rather, they innovate through con-
tinuous improvement of existing services, including NHS 
websites and the NHS app. That being said, NHS Digital 
has a specific drive for better data collection and easier 
patient–clinician interactions. With more than 700,000 users 
registered to the NHS app at the end of May 2020 [42], 
combined with over 90 million demographic records on the 
NHS Spine system [43], NHS Digital is an essential compo-
nent of the innovation pathway, particularly in the evidence 
generation phase. One example of this is the contribution 
of NHS Digital to the upcoming AI award, by producing 
synthetic datasets with the Medicines and Healthcare Prod-
ucts Regulatory Agency (MHRA) to optimise accuracy of 
algorithms [44].
NHSX
In comparison to NHS Digital’s more administrative role, 
NHSX reports directly to the Department for Health and 
Social Care and the Chief Executive of NHS England. They 
act as the oversight organisation to define the digital strategy 
envisioned by the Health Secretary [45], and other long-
term strategies, including the future remit of NHS Digital 
[46]. A specific focus of NHSX is to accelerate digitisation 
within the NHS by establishing centrally agreed standards 
and allowing local NHS organisations the freedom of choos-
ing their mode of delivery, if they meet the required open 
standards for interoperability, accessibility, and security 
[45]. They also prioritise cutting time spent by clinicians 
inputting and accessing data within the NHS system, ease 
of access to key NHS services by patients on their smart-
phone and ensuring secure and reliable access to essential 
diagnostic information in clinic [47].
The aim of NHSX to establish a data-driven ecosystem 
will not only allow patients to have easier and wider access 
to their personal data, but also easier circulation of the col-
lected data between patients, clinicians, and care systems. 
The increase in interoperability between different health 
institutes, by better data sharing practices including cloud 
storage, has the potential to improve patients’ access to ser-
vices, deliver the right diagnostic information to clinicians, 
and provide researchers with the healthcare data they need 
[48]. It would also provide an innovator friendly environ-
ment for easier product testing and initial health system 
adoptions. Furthermore, it assists in the goal of the AAC of 
achieving proper ‘demand signalling’, whereby researchers, 
innovators and funders can more easily understand what the 
NHS needs [49].
NIHR Funding Schemes
National Institute for Health Research (NIHR) is a UK gov-
ernment agency which funds research into health and care. 
It has a wide variety of programmes which support differ-
ent groups of research, spanning the research innovation 
pathway from early Minimal Viable Product development 
to evaluative research, including pragmatic clinical trials. 
NIHR schemes undergo regular mandated peer review, to 
ensure appropriate design and methodology.
The NIHR runs many schemes, some of which are spe-
cifically aimed at innovators [50], including the competi-
tive i4i (Invention for Innovation) award [51]. This has a 
track record of highly successful adoption and commerciali-
sation, although less than a quarter of applicants are suc-
cessful per year [52]. Life sciences companies can apply to 
most programmes as lead applicants, or in some cases, as 
co-applicants alongside industry, NHS and academic part-
ners. The i4i programme is a translational funding scheme, 
aimed at advancing medical technologies and interventions, 
especially in areas of high or rapidly increasing demand. In 
2020 this included the themed call of injuries, accidents, 
and urgent and emergency care [53] and more recently, the 
COVID-19 call [54]. It is split into three awards, Product 
Development Award (PDA), Challenge, and Connect, aimed 
at different stages of development.
With the goals of minimising investment risk and assist-
ing development of translational innovation into real ideas, 
the awards support both existing ideas, with research funding 
used to reach the next stage in the developmental pathway, 
and additional research for newly, CE (certification) marked 
products, where regulators such as NICE require more evi-
dence before adoption. All awards are aimed at products and 
services which aim to integrate into the NHS [55].
While the Challenge award supports assessment of medi-
cal innovations in the real-world, the PDA provides all jus-
tifiable expenses for translational research proposals [51]. 
Connect, on the other hand, is a programme centred on small 
and medium enterprises, focussing on helping early-stage 
products to build momentum and reach important business 
and technological milestones [51].
NIHR Artificial Intelligence Scheme
In August 2019, NHSX launched an AI Lab, using a £250 
million fund from the Department of Health and Social 
Care [56, 57]. £140 million of this has been made available 
over three years in the Artificial Intelligence in Health and 
Care Award [58], as a collaboration between NHSX, the 
AAC, and the NIHR. The aim of this award is to advance 
the development of AI technologies which meet the stra-
tegic aims of supporting data-driven decision making 
and optimising interactions between existing systems, as 
 Therapeutic Innovation & Regulatory Science
1 3
outlined in the NHS Long Term Plan [48]. The funding 
focuses on four NHS priority areas: screening, diagnosis, 
decision support and improving system efficiency [58]. 
Support is available across four phases of development 
(which are similar to the phases of drug development): 
Phases 1–3 are incorporated into NIHR’s i4i and SBRI 
(Small Business Research Initiative) award schemes, while 
Phase 4 is covered by NHSX via the AAC team. A call 
for applicants is made twice per year. The award provides 
awardees assistance in navigating issues in the develop-
mental process, highlighted by NHSX’s recent AI report 
[49] and digital innovator summary report [59]. These 
issues include the vital process of patient data access.
NHSX also runs a number of other projects to drive AI 
innovation in the NHS, under the umbrella of the NHS AI 
Lab. In 2020, the NHS AI Lab announced its Skunkworks 
project to find, fund and resource AI endeavours within the 
health and care ecosystem [60]. NHS colleagues can pitch 
problems with potential AI solutions in pitching-style events 
to identify real-life problems which can benefit from the 
expertise of the NHS AI Skunkworks team.
NHS Innovation Accelerator
Launched in 2015, the NHS Innovation Accelerator is an 
NHS England initiative delivered in partnership with Eng-
land’s 15 AHSNs and hosted at UCLPartners [61]. The 
Innovation Accelerator invites applications from individu-
als (clinical, industry, academia) as part of an annual inter-
national call. Applicants are required to demonstrate their 
skills and experience to qualify for support, alongside the 
efficacy and safety of the proposed innovation, as well as a 
strategy for scaling in the NHS [61]. The assessment panel 
is drawn from a wide range of organisations including NHS 
England and NHS Improvement, AHSNs, NICE and The 
Health Foundation. Successful Innovation Accelerator fel-
lows receive bespoke support, including access to mentor-
ship from a range of high-profile experts, links with AHSNs 
and other stakeholder organisations, peer-to-peer learning 
and support, a dedicated learning programme, and a bursary. 
Innovations can be of any type, including medical devices, 
apps, new models of care and artificial intelligence [62]. 
While the NHS Innovation Accelerator core team provides 
day-to-day support, AHSN partners provide signposting, 
local networking and support on scaling strategies.
The Innovation Accelerator has supported a number of 
successful innovative solutions during the COVID-19 pan-
demic, both in response to new demands and exacerbations 
of existing problems. Examples include ‘Echo’, an app 
allowing patients to order NHS prescriptions to their home 
for free, and ‘HaMpton’, which uses an app for home moni-
toring blood pressure during pregnancy [63].
Innovate UK
Innovate UK (formerly known as Technology Strategy 
Board) provides grants to companies that are working on 
projects that will develop something that can be classed 
as a “technology innovation”. Innovate UK is part of UK 
Research and Innovation (UKRI), and supports innovative 
ideas and business growth through grant funding, loans and 
procurement [64].
Innovate UK aims to invest in early-stage innovation pro-
jects with high potential as well as focussing on sectors it 
has identified as priorities. Each funding opportunity has 
different eligibility requirements but in general, eligible pro-






Innovate UK is not a health-specific pathway, but they do 
operate ‘catapult’ innovation centres, which focus around 
innovation in specific areas of health, such as the Medi-
cines Discovery Catapult [64]. They have collaborated with 
a range of other partners, including the charity LifeArc, 
the Multiple Sclerosis (MS) Society and The University of 
Manchester [66]. The Medicines Discovery Catapult has 
been particularly active during the COVID-19 pandemic, 
including through the coordination of the UK Lighthouse 
Labs Network and in providing leadership to the UK’s drug 
discovery community [67].
Medilink UK
Medilink UK is a not-for-profit, professional association and 
specialist health and life-science consultancy. Its primary 
focus is on fast tracking the development of Life Science 
companies by enhancing their connectivity to UK business, 
clinical, regulatory and finance communities, helping form 
new partnerships and navigate the increasingly complex 
health innovation landscape. Other services offered include 
market research, PR/communications, assistance with mar-
ket access (including international) and assistance with grant 
applications [68].
One of the benefits of Medilink to small and medium 
enterprises is the access to the NHS. Medlink has links with 
the regional AHSNs, and they also help companies with 
NHS market access strategy. For example, their Innovation 
Surgeries programme starts with an offer to all regional com-
panies, but especially small and medium enterprises who 
have a product or service that they believe should sell to the 
NHS and is either close to or on the market but struggling to 
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find buyers. Certain companies may also participate in the 
aforementioned regional ‘Test Beds’ programme in collabo-
ration with NHS trusts, CCGs and clinical trials units [69]. 
An example of a successful venture supported by Medilink 
UK is Deltex Medical, a company who produce the Car-
dioQ-ODMOesophageal Doppler Monitor (ODM), a mini-
mally invasive Doppler probe that can be inserted nasally or 
orally to measure circulating blood volume [70].
NHS Clinical Entrepreneur Programme
The NHS Clinical Entrepreneur Training Programme 
launched in 2016 as an entrepreneurial workforce develop-
ment programme to equip participants with the skills, knowl-
edge and experience required to develop innovations within 
the NHS [37]. Since the inception of the programme, it has 
trained over 500 healthcare professionals with mentoring, 
networking opportunities and teaching [37]. The programme 
is available to clinical and non-clinical NHS staff seeking to 
develop an idea for an innovation which may improve patient 
care. Such a programme is important in fostering a culture 
of improvement within the NHS, helping to encourage intra-
preneurship and reducing attrition rates of staff leaving to 
pursue entrepreneurial aspirations.
Alternative Pathways
For those seeking direct commercialisation, there are sev-
eral other options to support innovations that exist outside 
normal NHS and government structures. Funding can be 
provided by angel investors, venture capitalists and fam-
ily offices. Start-up accelerators provide capital too, often 
combined with close mentorship and upskilling of the team. 
Any venture can seek this type of funding, and the process 
involves a business pitch to the investors in question and 
often a series of interviews with the start-up team. There is 
no formal process for obtaining funding from venture capi-
talists and Angels and the process usually involves cold-
communication and networking.
Angel Investors
Angel investors are high net worth individuals who invest 
into the early formation of a start-up. In return for the provi-
sion of funding, angels usually get a stake in the company. 
Many angels have specific areas of expertise, so they can 
advise and help build the connections of the venture—this 
is because angels have a personal responsibility for the 
start-up’s success. Angels are attractive sources of capital 
since they afford more flexibility than investment banks 
(for example) and usually their loan does not have to be 
paid back if the venture fails. Angels are usually part of a 
larger network and intermediary agents such as MedCity (the 
umbrella organisation for London’s AHSCs and several uni-
versities [71]) work to connect them to life-science start-ups. 
An example of an established angel network is Cambridge 
Angels [72], while examples of life-science start-ups show-
ing success from such investment include Eagle Genomics 
and Smart Target [73].
Venture Capital
Venture capital is a type of financing invested in start-ups 
that are usually high risk but have the potential for rapid 
growth. The investments are usually larger than angels and 
so the venture should ideally have the management and stra-
tegic plan to scale quickly. Different venture capitalists oper-
ate at different stages in the venture’s life-cycle (from idea 
to adoption) [74]. The clear benefit for businesses is the lack 
of obligation to pay back lent money. Like angels, venture 
capitalists have business and institutional knowledge and 
are well connected, and again like angels, venture capital-
ists expect a return for their investment, usually through an 
acquisition or access to intellectual property. Many start-ups 
are wary of very large investments as they may risk losing 
management of the company. The oldest venture capitalist in 
the UK is Abingworth, which boasts a successful portfolio 
and series of exits [75].
Start‑up Accelerators/Incubators
Start-up accelerators and incubators provide intense train-
ing, upskilling and mentorship for select ventures, alongside 
funding. This is particularly important for early-stage spin-
outs (often projects started in university research groups) as 
it ‘accelerates’ the acquisition of strategic, managerial and 
commercial acumen. Some pre/seed stage venture capital-
ists and angels can offer similar help but this is not in the 
form of a structured programme such as these accelerators. 
Many are located at life-science venture ‘hot-spots’ such as 
Cambridge, United Kingdom. An excellent example is Start 
Codon [76], which leverages its connections with the bio-
medical hub in Cambridge to provide seed funding and train-
ing for innovators, particularly those taking an idea from 
academic research into a start-up, in return for an 8% stake 
in the final product [77].
Equity Crowdfunding
Crowdfunding is a fairly new model for ventures to secure 
capital. It allows life-science start-ups raise up to £1 m (and 
sometimes more) by attracting a small pool of investors. 
Equity crowdfunding gives more control to the entrepreneurs 
in terms of later funding and strategic decisions since the 
capital has been acquired by many individuals rather than 
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one body as in venture capital and angel investing. A great 
example of a body is Capital Cell and a recent success story 
is the French Antabio [78].
Healthcare Leadership Academy
Healthcare Leadership Academy is a social enterprise run 
privately by medical professionals aimed at providing skill-
based support for medics entering the entrepreneurship 
arena. It has teaching fellows from across the UK clinical, 
academic and health policy establishment. Similar to the 
AAC Clinical Entrepreneur Training Programme, it provides 
training rather than funding, although it operates indepen-
dently of the NHS [79].
Discussion
The goal of making the healthcare sector more efficient and 
effective in all three stages of innovation (invention, devel-
opment and implementation) is a primary concern for health 
companies and governments around the world [80]. There 
has been significant emphasis on improving the development 
and adoption of innovations in the UK since the 2000s, when 
a series of reports identified significant deficits in health-
care innovation in the NHS [4, 5, 19]. Since then, several 
pathways have been set up, operating across all stages of 
the innovation pipeline (Fig. 2), with their scope defined by 
location, technology area or stage of development, based on 
the specific problem identified when they were set up.
Despite this strong policy push, there remain significant 
barriers to achieving the political ambition of making the 
NHS the most innovative health system in the world [81]. 
While one might expect that national policy would be more 
easily implemented in a relatively unified health system 
such as the NHS, rather than more fragmented structures, 
in many areas the UK still lags behind. For example, the 
UK public are much less likely to use digital health services 
to track medical conditions compared to European nations, 
suggesting relatively low integration of digital health within 
the NHS compared to other health systems [82]. While aca-
demic literature exploring the current innovations pathways 
is limited, there have been efforts to evaluate the uptake and 
diffusion of innovation previously, perhaps most notably 
in the 2012 Innovation, Health and Wealth report, which 
recommended implementation of AHSNs to align innova-
tion with healthcare delivery and improve patient outcomes 
[83]. Since then, it has been suggested that budget silos and 
a lack of accountability for innovation may be hindering 
greater success of innovation pathways such as the AHSNs 
[18, 84, 85].
While the body of this paper has focussed on individual 
pathways, the following discussion will cover the major 
challenges for innovation in healthcare, and the extent 
to which the discussed pathways have addressed these 
challenges.
Challenges to Implementation: Connecting 
Stakeholders, NHS Bureaucracy and Interoperability
It is widely recognised that while the NHS, and the UK Life 
Sciences industry more generally, is world leading in the 
invention and early development of medical devices [86], 
there are significant barriers to implementing these inno-
vations [4]. One reason for this is the fragmented nature 
of the NHS, which presents a barrier particularly for small 
and medium enterprises who may be unaware of impactful 
regional variations, from digital infrastructure to bureau-
cratic structures. For example, companies seeking to intro-
duce digital health technology into NHS services will likely 
gain traction in urban areas such as Greater Manchester and 
London/South East, but might struggle much more in other 
parts of the country where primary care remains stubbornly 
paper-based [86].This may explain why informal clinical 
networks, long identified as a key component of innovation 
adoption [87], provided by the AHSNs and other regional/
local innovation pathways have been so successful. They 
can guide innovators through the particular landscape of 
their area, helping them overcome many of the traditional 
barriers to implementation, from market access to ensuring 
the continued use and improvement of innovations [18]. A 
recent example is the work of Oxford AHSN in aiding a per-
sonalised oncology company through the process of product 
testing and market access [88]. The need for regionalisa-
tion in delivering health services is exemplified in the initial 
problems faced by the national Track and Trace system for 
COVID-19 [89, 90]. Further regional and local integration 
will likely arise from the establishment of ICSs as the future 
of health and care delivery in England, as announced in 2021 
[10]. It is not yet clear how the new integrative ICSs will 
affect the local and regional economy of innovation, par-
ticularly given the other measures to centralise power in the 
NHS set out in the white paper, but it is expected that they 
will improve IT integration and enhance the sharing of data. 
Of course, the aim of interoperability within the NHS (the 
ability of NHS digital systems to talk to each other) [91], 
which is a major goal of NHSX [92], will allow improve-
ments in local integration to be scaled up to national coor-
dination of care, aligning with the goal set out in the NHS 
Long Term Plan to streamline and accelerate the innovation 
pipeline [2].
A remaining challenge for implementation lies in the 
overlapping nature of the innovation pathways, which could 
be described as being disjointed. This is in part due to the 
patch-work manner in which they were set up. While the 
recent establishment of the AAC as the parent body of the 
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NHS innovation landscape is a step in the right direction, 
providing a ‘front door’ to the confusing landscape of path-
ways, there remains a lot of work to do. The focus of the 
AAC on ‘demand signalling’, working out what innovation 
priorities the NHS has, is vital, and it is key that this receives 
both top-down and bottom-up (from CCGs and AHSNs) 
input [18]. This approach has already proved successful for 
specific services such as the RMOCs, where local bodies 
are able to suggest specific priorities for the region which 
are then approved by a national body; this takes into account 
both regional needs and national priorities [30]. A key role 
of the AAC must therefore be the identification of models 
of best practice, for wider dissemination through the innova-
tion landscape.
Challenges to Development: Prototyping 
and Testing
While a particular problem for NHS innovation is the 
confusing process of implementation, a general issue 
Fig. 2.  Innovation pathways in the context of the conventional innovation pipeline.
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for healthcare innovation is the process of development. 
Ranging from early clinical testing through to regulatory 
approval, the necessary safety and quality checks can repre-
sent a substantial barrier for innovators lacking connections 
and funds [93]. In this regard, local pathways including the 
NHS Vanguards and CCG Test Beds schemes have provided 
an invaluable asset to coordinate testing of innovative Med-
Tech, digital health solutions and care models. It is impor-
tant to note the NHS Long Term plan discusses plans to 
expand the Tests Beds scheme through to Regional Test Bed 
Clusters, with an increasing share of the NHS funding spent 
on real-world testing [2]. Similarly, the introduction of ICSs 
will further integration of health and social care, potentially 
further facilitating real-world evidence generation [10, 94]. 
At a regional level, the ARCs and AHSNs once again pro-
vide a crucial link across industry, NHS and academic stake-
holders, while at a national level schemes such as the NHS 
Innovation Accelerator and Medilink allow easier access to 
the AHSN network. This is particularly key when it comes 
to generating evidence for the marketing of a product, pre-
implementation across the NHS, and for gaining regulatory 
approval from EU and UK bodies and final adoption hurdle 
of HTA (Health Technology Assessment, which in England 
is conducted by NICE), the process of which is often very 
opaque [93].
Challenges to Development: Accessing Clinical Data
Another significant barrier in the development stage, on 
which significant progress has been made, is allowing 
access to patient data while maintaining patient confidenti-
ality. Ideally data should be homogeneous such that systems 
can continually improve and be more easily shared between 
healthcare providers. If data between facets of the NHS is 
homogeneous this permits interoperability and relatively 
simple application of the same technology elsewhere. The 
technology may also be reprogrammed to meet new and 
emerging needs or integrate with a growing pool of data. 
Ultimately, if interoperability within a health system is 
achieved then this ensures that the technology is self-refer-
ential. In this way, as more data is acquired the effectiveness 
of the system increases and network effects begin to emerge, 
such that once an early adopter hospital takes on the technol-
ogy the marginal benefit for each successive hospital now 
increases since the pool of data used to refine the technology 
continues to grow [92, 95].
Since 2019, NHSX has hosted efforts to establish a frame-
work for managing NHS Health Data [96]. This has been 
complimented by efforts by Health Data Research UK to 
build a world-leading health research database for innova-
tion [97]. However, the active work by NHS Digital and 
NHSX to improve the interoperability of NHS systems still 
has a long way to go, and this remains a major barrier to 
innovation in the UK [86].
One example of a successful innovation in the field of 
clinical data within the NHS is the digitalisation the ‘red 
book’ maternity record for parents to keep a record of their 
child’s development, including their immunisation records 
and growth [98]. This has the potential to be particularly 
useful in the long-term, with the NHS Long Term Plan not-
ing that this will help children start their lives with a digital 
Personal Health Record (PHR) [48].
Challenges to Invention: Accessing Funding 
and Support
The 2006 Cooksey review identified two translational gaps 
in the pipeline from laboratory to bedside [19]; firstly, trans-
lating basic research into new products, and secondly new 
products into clinical practice. Most innovation pathways 
focus on the latter gap, or later on in the first gap (i.e. from 
nascent product to tested prototype). Nevertheless, access 
to funding in the early stages of innovation is an issue, one 
which there is some support for. Much of this support lies 
outside traditional innovation pathways, such as venture 
capital and angel investors. Additionally, grant funding is 
available from university, government, private firm and EU 
sources [20].
The innovation pathways themselves provide help by 
guiding companies and individuals to funding, similar to 
how they provide access to testing. NIHR funding schemes 
also provide some direct funding, or links to investment, 
such as InnovateUK. This being said, a recent review high-
lighted the concern from NHS managers that austerity 
measures limit the amount of initial funding available from 
AHSNs [99], and that significant capital needs to be invested 
in the first place to access the benefits of AHSNs (i.e. the 
network of academia, clinicians and industry). Therefore, 
early funding from NHS sources remains a major area for 
improvement. The NIHR AI fund may provide a model for 
how NHS or Department of Health and Social Care fund-
ing can be used to encourage early-stage innovation in the 
future. We suggest that coordinating this should be a major 
role for the AAC going forward, through their Innovation 
Portal [100].
Challenges to Invention: Encouraging Innovation
An emerging theme of the innovation pathways is the util-
ity of the AHSN network as an asset for the coordination 
and guiding of innovators through the highly complex NHS 
innovation landscape, from the earliest invention stage right 
through to implementation. However, there is an even ear-
lier stage of innovation that exists that is often ignored, and 
lies outside the remit of the AHSNs; encouraging clinicians 
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(rather than more traditional academic/industry) to inno-
vate. An example of this is the AAC’s Clinical Entrepre-
neur Training Programme (see above) [37], which takes on a 
cohort of NHS clinicians and teaches them skills which will 
aid innovation (similar to the Healthcare Leadership Acad-
emy [79]). Alternatively, the NHS Innovation Accelerator 
aims to seed innovations specific to their themed calls (see 
above), giving clinicians a chance to develop innovations in 
areas most needed by the NHS. Applicants submit their cre-
dentials and potential ideas within these calls, rather than the 
more informal process available for other innovations. This 
is another example of the ‘demand signalling’ necessary to 
gain innovations that are most useful to the NHS.
Concluding Remarks
Our research indicates that there is a wide array of support 
available to innovators within the UK healthcare system. 
However, these support pathways are fragmented and there 
is notable redundancy among them. We suggest that expand-
ing and clearly defining the leadership role of the AAC in the 
innovation landscape would go some of the way to removing 
this fragmentation.
As we tend towards the development of digital innova-
tions, software and artificial intelligence, data homogenisa-
tion and interoperability will become increasingly important. 
Although already a goal of NHSX, we highlight this as a 
primary target for the NHS, as it could remove many of the 
current barriers to implementing innovations across regional 
and local NHS services. We also highlight the need for sup-
port for innovators at the earliest stages of the innovation 
process, invention. A lack of seed funding or support for 
those with a promising idea can act as a barrier to entry even 
if later stages of innovation development are well-supported.
While we have been able to provide a broad overview 
of the innovation landscape in the NHS, our research has 
been limited by the lack of primary literature on this topic, 
including few papers with input from innovators and clini-
cians. There is therefore a pressing need for a high-quality, 
independently funded review of the innovation landscape, 
as many of the above pathways have received no review, or 
if they have, they tended to be reviewed either by their own 
members, or by reviewers funded by the organisation under 
scrutiny. This could lead to bias in reporting and evaluation, 
whether real or perceived [101]. Such a review would ideally 
include a survey of relevant stakeholders to gain an insight 
into practical challenges faced by those who work with the 
pathways.
Given the broad range of innovation pathways within and 
around the NHS, it is no surprise that the NHS is a leading 
force in driving healthcare innovation globally. There is an 
array of support available for clinical innovators as well as 
for others seeking to improve patient care. Indeed, there are 
also opportunities for patients themselves to drive innova-
tion and many of the pathways strongly encourage patient 
and public involvement. The pace at which these innova-
tion pathways are growing offers an exciting prospect for the 
future of healthcare delivery in the United Kingdom.
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